I studied medicine at Cambridge and St Thomas’s Hospital and after qualifying trained as a surgeon in London and Cambridge before undertaking a period of research at the University of Cambridge under the supervision of Professor Sir Roy Calne.
In 1988 I was appointed Visiting Assistant Professor of Surgery at Indiana University Medical Center, USA, where I was responsible for initiating a programme of liver transplantation. I returned to the UK in 1989 to take up the post of University Lecturer (honorary consultant) in the University Department of Surgery at Cambridge. I was the Clinical Director of the Cambridge Transplant Unit and also a Fellow and Director of Studies in Medicine at Magdalene College, Cambridge. I was appointed to my current post in 1999.
Professor of Transplantation
- Consultant Transplant and HPB Surgeon
- Director Oxford Transplant Centre
My experimental interest is in the application of isolated perfusion of the liver to a number of therapeutic areas. In particular, perfusion of the liver with oxygenated blood at normal body temperature can allow recovery from damage, extended preservation for transplantation and organ specific delivery of therapy.
Clinical research studies include small scale pilot studies of novel immunosuppressive strategies and the organisation of a multi centre national trial.
The impact of intestinal transplantation on quality of life.
Ambrose T. et al, (2020), Clin Nutr, 39, 1958 - 1967
Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials.
Sawitzki B. et al, (2020), Lancet, 395, 1627 - 1639
An analysis of the association between older recipient age and outcomes after whole organ pancreas transplantation.
Mittal S. et al, (2020), Transpl Int
Novel Organ Perfusion and Preservation Strategies in Transplantation - where are we going in the UK?
O'Neill S. et al, (2020), Transplantation
Outcomes of associating liver partition and portal vein ligation for staged hepatectomy as primary indication versus as a salvage procedure after insufficient future liver remnant hypertrophy following portal vein embolisation
Smilevska R. et al, (2019), BRITISH JOURNAL OF SURGERY, 106, 20 - 20